DNA-damaging therapies represent the most frequently used non-surgical anticancer strategies in the treatment of human tumors. These therapies can kill tumor cells, but at the same time they can be particularly damaging and mutagenic to healthy tissues. The efficacy of DNAdamaging treatments can be improved if tumor cell death is selectively enhanced, and the recent application of poly-(ADP-ribose) polymerase inhibitors in BRCA1/2-deficient tumors is a successful example of this. DNA damage is known to trigger cell-cycle arrest through activation of DNA-damage checkpoints. This arrest can be reversed once the damage has been repaired, but irreparable damage can promote apoptosis or senescence. Alternatively, cells can reenter the cell cycle before repair has been completed, giving rise to mutations. In this review we discuss the mechanisms involved in the activation and inactivation of DNA-damage checkpoints, and how the transition from arrest and cell-cycle re-entry is controlled. In addition, we discuss recent attempts to target the checkpoint in anticancer strategies.
Introduction
To maintain genome integrity, cells need to adequately respond to various modes of genotoxic stress. This is achieved by activation of evolutionarily conserved DNA-damage response (DDR) pathways that abrogate cell-cycle progression when the genome is damaged and stimulate DNA repair. Depending on the extent of DNA damage, cells either manage to repair all lesions and re-enter the cell cycle (checkpoint recovery), or they are eliminated by programmed cell death (apoptosis). Alternatively, cells can remain permanently arrested after a DNA-damaging insult (senescence). Activation of the components of DDR pathway that allows efficient DNA repair has been recently reviewed extensively elsewhere (Bekker-Jensen and Mailand, 2010; Ciccia and Elledge, 2010; Polo and Jackson, 2011) . This review will focus on the mechanisms that activate checkpoints after genotoxic stress and silencing of checkpoints during the recovery process that can occur after successful repair of the damage.
Activation of DNA-damage checkpoints
In general, activation of DNA-damage checkpoints is enabled by recognition of DNA damage by sensors, followed by an ordered activation of upstream and effector kinases, the latter of which can directly target the major cell-cycle control machinery ( Figure 1a ). DNA damage can induce a cell-cycle arrest in the G 1 , intra-S or G 2 phase of the cell cycle. Depending on the phase of the cell cycle when damage occurs, and the mode of DNA damage, cells can activate distinct pathways in response to genotoxic stress.
The primary response to DNA damage is accomplished by upstream kinases of the phosphatidylinositol-3-OH kinase-related family, which includes ATM (ataxia teleangiectasia mutated kinase), ATR (ATMand Rad3-related kinase) and DNA-PK (DNA-dependent protein kinase). Whereas ATM and DNA-PK are activated by double-strand breaks (DSBs), ATR responds to a broader spectrum of DNA-damaging lesions that generate single-stranded DNA (including stalled replication forks caused by bulky base adducts or UV photoproducts). This simplistic view, however, is in fact more complex because DSBs are processed during the S/G 2 phases of the cell cycle by the endonuclease CtIP and generate single-stranded DNA lesions leading to a secondary activation of the ATR (Jazayeri et al., 2006; Sartori et al., 2007) . All phosphatidylinositol-3-OH kinases responding to DNA damage show similar substrate specificities, and recent phosphoproteomic screens reveal a substantial overlap of their substrates (Matsuoka et al., 2007; Bennetzen et al., 2010; Bensimon et al., 2010) . The best example is probably the histone variant H2AX, which is rapidly phosphorylated at Ser-139 (producing gH2AX) by ATM/ATR or DNA-PK in the chromatin flanking the damage site. On the other hand, these kinases also have some exclusive substrates, which are not shared by the other members. Thus ATM phosphorylates checkpoint kinase-2 (Chk2) at Thr-68, whereas ATR phosphorylates Chk1 at two residues, Ser-317 and Ser-345 (Bartek and Lukas, 2003) . In general, phosphorylation of Chk2 and Chk1 leads to their activation and further transmission of the checkpoint signal (see below).
Activation of the upstream checkpoint kinases requires the recognition of the DNA lesion. In case of DSBs, this is achieved by the Mre11-Rad50-Nbs1 complex that directly binds to the exposed ends of the DNA, recruits ATM and initiates its activation (Falck et al., 2005) . Active ATM generates gH2AX at the surrounding chromatin, which is recognized by phosphopeptide-binding BRCT domains that are present in many proteins involved in the DDR, and serves as a docking site for a large adaptor protein, MDC1 (Stucki et al., 2005) . Recruitment of multiple additional components of the checkpoint then follows in an orderly manner, including RNF8, RNF168, HERC2, 53BP1 and BRCA1 (reviewed elsewhere Bekker-Jensen and Mailand, 2010) . In general, recruitment of these proteins to the chromatin is essential for efficient DNA repair and may also have some role in further amplification of the checkpoint signaling (that is, by recruiting more ATM) Shibata et al., 2010) . ATM is rapidly autophosphorylated at Ser-1981, which was originally proposed to induce the dissociation of an inactive homodimer into active monomers (Bakkenist and Kastan, 2003) . However, mice lacking the corresponding ATM autophosphorylation sites are still able to fully activate the checkpoint after exposure to ionizing radiation (IR), strongly suggesting that ATM autophosphorylation is not an essential step for its activation (but a useful marker of ATM activity) (Pellegrini et al., 2006) . Instead, DNA damage-induced acetylation of ATM at Lys-3016 by the acetyltransferase Tip60 was recently proposed to activate the ATM (Sun et al., 2005 (Sun et al., , 2007 . In this model, Tip60 is recruited to DSBs by a direct interaction with the Mre11-Rad50-Nbs1 complex and its enzymatic activity toward ATM is increased after binding of its chromodomain to trimethylated histone H3 (H3K9me3) (Sun et al., 2009; Chailleux et al., 2010) .
By contrast, single-stranded DNA lesions (such as the stalled replication forks or resected DSBs) are rapidly coated by replication protein-A complexes, which further recruit and activate ATR in a stable complex with its cofactor ATRIP (Zou and Elledge, 2003) . In parallel, replication protein-A binds to Rad17 and recruits a ring-shaped trimeric complex, Rad9-Hus1-Rad1 (9-1-1), to the site of damage. This 9-1-1 complex is then phosphorylated by ATR and can bind to the BRCT domains of an adaptor protein, TopBP1, which further boosts the activity of ATR (Cimprich and Cortez, 2008) . RHINO, a recently identified 9-1-1-and TopBP1-interacting protein, is required for efficient activation of ATR (Cotta-Ramusino et al., 2011) . Active ATR has several hundreds of substrates, including Chk1, which is essential for induction of the checkpoint response. Importantly, Chk1 needs to form a complex with a mediator protein, claspin, to be efficiently activated by ATR (Chini and Chen, 2003; Kumagai et al., 2004) . Upon phosphorylation, Chk1 is released from the chromatin and can freely diffuse through the nucleus to phosphorylate multiple substrates to establish the checkpoint response (see below) .
Checkpoint kinases-effectors of the checkpoint
Proliferating cells repeatedly pass through the G 1 (growth phase), S (replication of DNA) and G 2 phases Figure 1 (a) Checkpoint activation. DNA damage is recognized by various sensor and adaptor proteins, which leads to activation of ATM and ATR kinases and allows establishing of a DNA-damage checkpoint. The major components activated during this response are Chk1 and p53 (green). Chk1 regulates cdc25A/B/C and Wee1, which leads to inhibitory phosphorylation of Cdk (yellow dots), prevents its activation (red) and causes cell-cycle arrest. p53 is stabilized by multiple posttranslational modifications (dots), and by increasing the transcription of a Cdk inhibitor, p21, and repressing the transcription of cyclin-B, it contributes to inhibition of cyclinCdk. In addition, cells activate the Chk2 and p38/MK2 pathways that are involved in apoptosis and checkpoint maintenance, respectively. (b) Recovery from the G 2 checkpoint. After DNA repair, multiple proteins are de-phosphorylated by Wip1 phosphatase, which leads to silencing of the checkpoint signaling and inactivation of p53. In parallel, Plk1 kinase targets claspin and Wee1 for degradation, and activates Cdc25A/B/C, which allows activation of cyclin-B-Cdk1 and checkpoint recovery.
of the cell cycle, followed by nuclear division (mitosis) and cellular division (cytokinesis (Mailand et al., 2000) . Destruction of Cdc25A is executed by bTrCP-SCFdependent ubiquitination and proteasomal degradation, and is induced by Cdc25A phosphorylation at Ser-76 mainly by Chk1 (Jin et al., 2003 (Jin et al., , 2008 . Chk1 also autophosphorylates at Ser-296, which generates a motif recognized by 14-3-3g that mediates the interaction of Chk1 with Cdc25A (Kasahara et al., 2010) . In parallel, Chk1 also activates Nek11 (Never in mitosis gene-Arelated kinase-11), which further phosphorylates Cdc25A at Ser-82 and enables its recognition by the bTrCP-SCF (SKP/Cullin/F-box protein) complex (Melixetian et al., 2009) . The ATM-Chk2 pathway was originally also suggested to be involved in the degradation of Cdc25A (Falck et al., 2001) ; however the finding that IR-induced degradation of Cdc25A in HCT116-Chk2 À/À cells occurs with the same kinetics as in wt-HCT116 cells indicates that the contribution of Chk2 to degradation of Cdc25A is either functionally redundant or occurs in a cell type-specific manner (Jin et al., 2008) . In addition, Cdc25B and Cdc25C are phosphorylated by Chk1/2 at Ser-323 and Ser-216, respectively, and are functionally inactivated by binding to 14-3-3 proteins (Peng et al., 1997; Sanchez et al., 1997; Forrest and Gabrielli, 2001) . Nonetheless, mice deficient in Cdc25B and Cdc25C are still able to fully activate the DNAdamage checkpoints, indicating that mere regulation of Cdc25A is sufficient to establish the checkpoint (Ferguson et al., 2005) . This observation is in line with the current view of functional redundancy in the molecular machinery that controls the G 2 /M transition (Lindqvist et al., 2009b) . In addition to its effect on Cdc25A, Chk1 can also phosphorylate and activate Wee1 kinase, which can directly increase the inhibitory modification of Cdk2 and Cdk1 (O'Connell et al., 1997) .
Importantly, the role of Chk1 in checkpoint control is evolutionarily conserved from yeast to humans and human Chk1 operates by the same molecular mechanisms as its yeast homolog (Sanchez et al., 1997) . Chk2 (homologous to Rad53 and Cds1 in yeast) is structurally distinct from Chk1, but both kinases share similar substrate specificity and may therefore have overlapping substrates. Data from Chk2-knockout mice and also from HCT116-Chk2 À/À human colon cancer cells indicate that, in contrast to yeast, Chk2 is functionally redundant in checkpoint activation in higher eukaryotes (Jack et al., 2002; Jin et al., 2008) . Instead, Chk2 seems to adopt a unique role in the regulation of the apoptotic pathways induced by DNA damage, as Chk2 À/À mice are more resistant to IR compared with the control animals Takai et al., 2002) . IR stimulates ATM to activate Chk2 by phosphorylation at Thr-68, which in turn leads to stabilization of the tumor suppressor p53 and promotes the transcription of several pro-apoptotic genes such as Bax, Puma and Noxa (Ahn et al., 2000; Hirao et al., 2000 Hirao et al., , 2002 Takai et al., 2002) . Phosphorylation of p53 at Ser-20 was originally proposed to be responsible for the Chk2-dependent activation of p53; however, this modification was retained in Chk2
À/À cells as well as in Chk2-depleted cells, suggesting that additional mechanisms may exist by which Chk2 modulates apoptotic responses (Ahn et al., 2003; Jallepalli et al., 2003) . Indeed, Chk2 has also been reported to regulate apoptosis after treatment with etoposide in an p53-independent manner through phosphorylation of E2F1 (Stevens et al., 2003) . Chk2 seems to be specifically involved in regulating apoptotic responses to agents causing DSBs as UV-induced apoptosis is not affected in Chk2
À/À cells (Hirao et al., 2000) . This is in good agreement with Chk2 being specifically activated by ATM but not ATR. Strikingly, the functional redundancy of Chk2 for checkpoint activation is lost when cells lose p53 . In contrast to p53-proficient cells, depletion of Chk2 in p53-deficient cells interferes with the IR-induced checkpoint arrest . Reasons for rewiring of checkpoint-activating pathways in p53-deficient cells are currently unclear; however, an interesting possibility is that, by losing p53, higher eukaryotic cells simply regain similar molecular pathways that act in yeast and that were suppressed during evolution.
Another mechanism implicated in G 1 checkpoint induction is rapid degradation of cyclin-D1 after exposure to IR (Agami and Bernards, 2000) . Degradation of cyclin-D1 is believed to release the Cdk inhibitor p21 from Cdk2/cyclin-D1 complexes, which in turn allows p21 to inhibit Cdk2/cyclin-E and prevent the G 1 /S transition. Degradation of cyclin-D1 was originally reported to depend on a destruction motif within cyclin-D1 and ubiquitination by the APC E3 ligase complex (Agami and Bernards, 2000) . However, recent evidence suggests that after DNA damage, cyclin-D1 is ubiquitinated by the SCF E3 ligase complex and this depends both on phosphorylation of cyclin-D1 at Thr-286 by glycogen synthase kinase-3b and a direct phosphorylation of the F-box protein FBXO31 by ATM (Santra et al., 2009 ). Thus, it is possible that the precise mechanism by which cells degrade cyclin-D1 after DNA damage is cell type-dependent. Moreover, it also appears that DNA damage specifically induces the degradation of cyclin-D1 (but not cyclins D2 and D3) indicating that the role of this pathway in the DDR in G 1 might depend on the expression profile of D-type cyclins in various tissues.
Finally, p38 and its downstream effector MAPKAP kinase-2 (MK2) have recently been implicated in the DDR in G 2 after exposure to UV (Bulavin et al., 2001; Manke et al., 2005) . The contribution of p38 to the DDR was attributed to the phosphorylation of cdc25B and cdc25C by MK2 (Manke et al., 2005) . Moreover, rapid and transient activation of the p38/MK2 pathway was also reported after IR, or treatment with doxorubicin or alkylating agents such as methyl methanesulfonate (MMS) (Mikhailov et al., 2004; Raman et al., 2007; Lafarga et al., 2009; Phong et al., 2010) . Activation of the p38/MK2 branch of the checkpoint has been reported to involve ATM/ATR-dependent activation of Thousand and one amino acid protein kinases (TAO) that belong to the MAPKKK family. TAO-dependent phosphorylation of MEK3 and MEK6 than induces the activity of p38 (Raman et al., 2007) . In addition, the p38 pathway might be involved in the initiation of the G 1 checkpoint by a rapid stabilization of p21 mRNA caused through phosphorylation of the mRNA-binding protein HuR by p38 at Thr-118 (Lafarga et al., 2009) . Despite all this, the role of the p38 pathway in checkpoint activation has recently been challenged when p38 pathway was suggested to have an essential role in survival after DNA damage through induction of multiple survival genes (Phong et al., 2010) . In addition, p38/MK2 seems to be involved in checkpoint maintenance (see below). Thus, the precise role of the ATM/ATR-p38-MK2 pathway in DDRs remains incompletely understood and it is possible that it largely depends on the mode and amplitude of DNA damage.
Checkpoint maintenance
An appropriate checkpoint response to genotoxic stress needs to be fast enough to prevent transition to the next phase in the cell cycle with damaged DNA, but durable enough to allow time for efficient DNA repair. Recent work has made it clear that induction and maintenance of the checkpoints are governed by distinct molecular mechanisms. As discussed above, the fast checkpoint induction largely depends on the transmission of the signal through phosphorylation of multiple substrates by ATM/ATR and Chk1/2 kinases, affecting their activity, protein stability or both. Conversely, pathways that depend on changes in the transcription of target genes act considerably slower and are mainly involved in checkpoint maintenance. The best-studied example of checkpoint maintenance is the contribution of the tumor suppressor p53 and its transcriptional target p21. p53 is extensively modified posttranslationally, especially in the N-terminal transactivation domain (including phosphorylation of Ser-15 and Ser-20 by ATM/ATR/DNA-PK and Chk1/2, respectively) and in the C-terminal regulatory domain (including acetylation of Lys-382 and Lys-320 by CBP/p300 and PCAF, respectively), which together reduce the affinity of p53 for its negative regulator Mdm2. This allows stabilization and tetramerization of p53; promotes association of p53 with transcriptional coactivators (or co-repressors); and binding of p53 to the promoters of its multiple target genes (for a recent review on p53 posttranslational modifications see Dai and Gu (2010) ). One of these, the cyclin-dependent kinase inhibitor p21, binds to and inhibits the cyclin-E/Cdk2 and cyclin-A/Cdk2 complexes, and has a major role in the control of G 1 arrest. Similarly, p21 also contributes to maintenance of the G 2 checkpoint (Bunz et al., 1998) . In addition, p53 can also control the G 2 checkpoint independently of p21 through transcriptional repression of mitotic inducers, including cyclin-B, cdc25B and polo-like kinase-1 (Plk1) (Imbriano et al., 2005; McKenzie et al., 2010; Dalvai et al., 2011) .
Interestingly, recent data indicate that the dynamics of p53's response to IR does not occur in a linear manner but instead appears in multiple repeating pulses with fixed amplitude and duration (Lahav et al., 2004; Batchelor et al., 2008) . These oscillations had long remained masked owing to averaging across a population of cells, but their observation became possible with recent advances in single-cell imaging techniques (Batchelor et al., 2009) . The oscillatory behavior of p53 is induced by activation of p53 by ATM at the time DNA damage is present, which subsequently results in the transcriptional activation of Mdm2 and Wip1 (see below), both negative regulators of p53, which establish negative feedback loops (Batchelor et al., 2009) (Figure 2 ). In response to DSBs, cells stabilize p53, generating the first pulse, which is then followed by pulses of a similar intensity repeating in 4-to 7-h intervals until the DNA is fully repaired. Strikingly, spontaneous pulses of p53 expression of comparable intensity can also occur in normal cycling cells; however, posttranslational modifications keep p53 inactive in the absence of sustained damage (Loewer et al., 2010) . By contrast, UV irradiation causes an induction of p53, but does not induce oscillations as seen after IR. Instead, UV induces a single p53 pulse the amplitude of which increases with the dose of UV (Batchelor et al., 2011) . The role of IRinduced p53 pulses in determining cell fate still needs to be addressed fully; however, it opens up an exciting possibility that, by recurring phases of strong checkpoint output with weak checkpoint output, cells can sense the actual strength of the DNA damage and can prevent inappropriate initiation of apoptotic cell death (Batchelor et al., 2009) .
Importantly, the DDR in G 1 is primarily dependent on p53. As a consequence, cancer cells that have lost p53 fail to establish a G 1 arrest in response to DNA damage, but arrest in G 2 instead, a response that remains relatively intact also in cancer cells (Kuntz and O'Connell, 2009 ). This implies that, apart from p53, additional mechanisms must exist to prevent p53-deficient cells from entry into mitosis with damaged DNA. Survival of p53-deficient cells after DNA damage was recently reported to depend on the p38/MK2 pathway (Reinhardt et al., 2007) . Whereas the Chk1 pathway was found to be important to establish the G 2 checkpoint, the p38/MK2 pathway was shown to be critical for long-term maintenance of the G 2 checkpoint . Strikingly, Chk1 and MK2 kinases share the same optimal phosphorylation motif (Arg-X-X-pSer/Thr) and thus may have overlapping substrates (Manke et al., 2005) . However, this does not appear to be the entire story, as both kinases show a distinct subcellular distribution after treatment with doxorubicin. Whereas Chk1 remains mainly nuclear after DNA damage, activated MK2 rapidly redistributes to the cytoplasm, where it phosphorylates distinct substrates . By phosphorylating an RNA-binding protein hnRNPA0 and a ribonuclease PARN, activated MK2 induces the accumulation of growth arrest and DNA-damage-inducible protein-a (GADD45a) mRNA, leading to increased protein levels of GADD45a . In turn, GADD45a was suggested to act in a positive feedback loop and to induce p38/MK2-dependent phosphorylation of cdc25B/C, binding of 14-3-3 protein and cytosolic sequestration of cdc25B/C . This finding is in line with the observation that the pro-survival activity of GADD45a in hematopoietic cells exposed to UV depends on the p38 pathway (Gupta et al., 2006) . However, GADD45a was also reported to directly associate with and inhibit cyclin-B/Cdk1 Zhan et al., 1999) , and thus it is possible that GADD45a prevents premature mitotic entry through multiple independent mechanisms. In addition, the p38 pathway was also reported to regulate checkpoint maintenance through stabilization of p27Kip, which can further suppress any residual Cdk activity in case the DNA damage persists Liontos et al., 2010) .
As checkpoints need to be maintained until the DNA damage is fully repaired, DNA-repair pathways are likely to be functionally connected with checkpoint signaling. Indeed, short interfering RNA screens for DNA repair factors involved in checkpoint regulation revealed that two homologous recombination-repair proteins, BRCA2 and PALB2, are required for G 2 checkpoint maintenance (Cotta-Ramusino et al., 2011; Menzel et al., 2011) . It is possible that by using DNArepair factors, cells coordinate checkpoint signaling with ongoing DNA repair; however, the exact mechanism by which BRCA2 and PALB2 communicate with the checkpoint still remains to be explored.
Silencing of checkpoints by phosphatases and checkpoint recovery
After successful DNA repair, cells re-enter the cell cycle in a process called checkpoint recovery. Owing to the inactivation and degradation of a multitude of cellcycle-regulatory proteins, which occurs in response to DNA damage, cells that are arrested in response to DNA damage are biochemically different from undamaged cells in the same phase of the cell cycle. This has the consequence that the cell-cycle machinery operates differently during recovery as compared with control of the cell cycle in unperturbed cells. Currently, the best understood mechanisms that promote recovery are mechanisms responsible for checkpoint recovery from the G 2 checkpoint (Figure 1b) . Whereas there is a considerable degree of functional redundancy in mechanisms regulating unperturbed G 2 /M progression, certain pathways become essential when cells recover from DNA damage (Lindqvist et al., 2009b) . In particular, this is true for Plk1 (and its yeast homolog cdc5) depletion or inhibition of which does not affect normal mitotic entry but completely blocks checkpoint recovery (Toczyski et al., 1997; van Vugt et al., 2004; Le´na´rt et al., 2007) . Plk1 contains a conserved threonine residue (Thr-210) within the T-loop, which has to be phosphorylated to fully activate Plk1 (Jang et al., 2002) . In late G 2 , Aurora-A kinase, together with its cofactor, hBora, phosphorylates Plk1 at Thr-210, resulting in activation Plk1 (Macurek et al., 2008; Seki et al., 2008) . In response to DNA damage, activity of Plk1 is kept low through inhibition of Thr-210 phosphorylation (Smits In unstressed cells, basal levels of p53 are kept low by Mdm2-dependent degradation. In response to IR-induced damage, ATM is activated and phosphorylates p53 and Mdm2 both resulting in stabilization of p53. Active p53 stimulates the transcription of Mdm2 and Wip1 mRNA, which leads to a delayed increased expression of these proteins. In turn, Wip1 de-phosphorylates p53, ATM and Mdm2, generating negative feedback loops that lead to destabilization of p53. This response results in regular oscillations of p53 levels until the DNA damage is repaired. Spontaneous pulses of p53 transcription can be generated by transient damage that occurs during the cell-cycle phase associated with intrinsic DNA damage. , 2010) . As a result, Plk1 effectively prevents further activation of both Chk1/2 and contributes to activation of cyclin-B/cdk1 complexes, stimulating checkpoint silencing and recovery at multiple levels (van Vugt et al., 2004) . In addition, Plk1 phosphorylates G 2 -and S-phase-expressed protein-1, which acts as a negative regulator of p53 and thus Plk1 activity contributes to suppression of p53 during checkpoint recovery (Liu et al., 2010) . Plk1 activity is essential but not sufficient for checkpoint recovery, indicating that additional control mechanisms exist. Among them, phosphatases, which counteract the multitude of protein phosphorylations implemented by the checkpoint machinery, are likely candidates to be involved in silencing the checkpoint and promoting checkpoint recovery . Data analysis from large phosphoproteomic screens indicates that phosphatases may have a more active role in the regulation of DDRs than originally anticipated (Bensimon et al., 2010) . So far the only well-characterized phosphatase that has been described to actively participate to establish the cellcycle arrest is PP2A in complex with its regulatory subunit, B56g. Thus, B56g is stabilized in an ATMdependent manner and activates p53 through dephosphorylation of pThr-55 (Li et al., 2007; Shouse et al., 2011) . On the other hand, the major cellular phosphatase PP2A has also been shown to limit basal phosphorylation of ATM-pSer-1981, Chk2-pThr-68, Chk1-pSer-317 and gH2AX (Goodarzi et al., 2004; Chowdhury et al., 2005; Leung-Pineda et al., 2006; Carlessi et al., 2010; . By keeping a relatively high basal activity of PP2A, cells can therefore prevent inadequate activation of the checkpoint under normal conditions. DNA damage (perhaps when exceeding a certain threshold) rapidly disrupts the interaction of PP2A with ATM, Chk1 and Chk2, allowing full activation of the checkpoint (Goodarzi et al., 2004; Carlessi et al., 2010; . Similarly, PP1 phosphatase in complex with its chromatin-targeting subunit, Repo/Man, was recently demonstrated to inhibit the activity of ATM under unstressed conditions, thus determining the threshold for activation of the DNA-damage checkpoint (Peng et al., 2010) . It is possible that after successful DNA repair, the reestablished interaction of PP2A and/or PP1 with various components of the DDR pathway helps to revert protein phosphorylation back to the original level, contributing to the silencing of the checkpoint. However, it remains unclear to what extent cells actively regulate these phosphatases during the DDR.
More is known about the contribution of phosphatases to checkpoint silencing and recovery. Recent data from several groups indicate that a PP2Cd phosphatase (PPM1D, hereafter referred to as Wip1) has a central role in termination of the checkpoint signaling and in checkpoint recovery Le Guezennec and Bulavin, 2010) . Several lines of evidence suggest that the function of Wip1 is tightly linked with regulation of the DDR. First, depletion of Wip1 by RNA interference results in prolonged checkpoint activation whereas overexpression of Wip1 causes efficient checkpoint override, indicating that Wip1 has the potential to regulate checkpoint signaling (Lu et al., 2005; Lindqvist et al., 2009a) . Second, the substrate specificity of the Wip1 seems to correspond with the motifs phosphorylated during the DDR, namely pSQ/pTQ motifs that are selectively phosphorylated by ATM/ATR and the pTxpY motif in p38 that is also phosphorylated in response to DNA damage (Yamaguchi et al., 2007) . By recognizing such motifs, Wip1 could efficiently target all of the substrates of ATM/ATR, and this is has thus far been confirmed for ATM-pSer-1981, Chk1-pSer-317, Chk2-pThr-68, p53-pSer-15, Mdm2-pSer-395 and gH2AX (Takekawa et al., 2000; Fujimoto et al., 2005; Lu et al., 2005 Lu et al., , 2007 Shreeram et al., 2006a; Cha et al., 2010; Macurek et al., 2010; Moon et al., 2010) . Third, PPM1D is a target gene of p53 and expression of Wip1 is increased after genotoxic stress (Fiscella et al., 1997) . Like this, cells can cycle with low levels of Wip1 (limiting the risk of an undesired de-phosphorylation of any phosphoprotein involved in normal cell progression), whereas DNA damage releases a negative feedback loop in which expression of Wip1 will limit the amplitude of the checkpoint to prevent an irreversible arrest. Fourth, premature translation of Wip1 mRNA is blocked by miR-16, which is also induced by genotoxic stress . This mechanism assures that early after DNA damage Wip1 levels are kept low to allow efficient checkpoint induction and DNA repair. Fifth, Wip1 is a nuclear protein and is enriched at the chromatin, where it can get in close contact with the proteins of the DDR pathway (Macurek et al., 2010) . Finally, although Wip1 is not present in yeast, it appears that low eukaryotes use the same family of PP2C phosphatases (namely Ptc2 and Ptc3) to regulate checkpoint recovery, indicating partial conservation in evolution (Leroy et al., 2003) .
Among many substrates of Wip1, p53 seems to have a special role in checkpoint recovery. We have noted that even complete inhibition of Chk1/2, ATM/ATR and p38 is not sufficient to promote recovery in Wip1-depleted cells (Lindqvist et al., 2009a) . On the other hand, cells lacking both Wip1 and p53 recovered normally, indicating that p53 is the crucial target of Wip1 to control recovery. This also implies that dephosphorylation of all other Wip1 substrates is less relevant for efficient recovery. What is more, we could show that Wip1 is required throughout the checkpoint response, not just at the stage that the checkpoint is definitively terminated (Lindqvist et al., 2009a) . This means that the activity of Wip1 is required throughout the DNA-damage checkpoint to prevent excessive p53 activation and is essential to retain checkpoint recovery competence (Lindqvist et al., 2009a) . Interestingly, Wip1 can regulate p53 by multiple mechanisms. Apart from direct de-phosphorylation of pSer15 on p53, Wip1 has been shown to activate the ubiquitin E3 ligase mdm2, which targets p53 for proteasomal degradation, and activate MdmX, which directly inhibits the transcriptional activity of p53 (Lu et al., 2005 (Lu et al., , 2007 Zhang et al., 2009) . Which one of these mechanisms is the most physiologically relevant is currently unclear; however, counteracting p53's function seems to be the major role for Wip1 to prevent an irreversible cell-cycle arrest. In addition, the two negative feedback loops in which Wip1 inactivates p53 and ATM are required to establish the dynamic behavior of the p53 response that follows after DSBs (see above).
Importantly, Wip1 is overexpressed (usually because of amplification of the 17q23 locus) in multiple human cancers, including medulloblastomas, neuroblastomas, breast, ovarian and gastric carcinomas (Bulavin et al., 2002; Li et al., 2002; Saito-Ohara et al., 2003; Castellino et al., 2008; Tan et al., 2011) . Moreover, overexpression of Wip1 is linked to poor prognosis in lung adenocarcinoma (Satoh et al., 2011) . High expression levels of Wip1 are usually found in tumors that retain wild-type p53, whereas overexpression of Wip1 is rare in tumors carrying mutations or lacking p53 (Bulavin et al., 2002) . Strikingly, Wip1-knockout mice are viable and are resistant to oncogene-induced as well as spontaneous cancer development (Bulavin et al., 2004; Harrison et al., 2004; Belova et al., 2005; Nannenga et al., 2006; Shreeram et al., 2006b) , suggesting that inhibition of Wip1 activity may potentially be beneficial in cancer therapy.
During prolonged checkpoint activation, cells need to maintain expression of critical cell-cycle regulators above a minimal level to remain competent for eventual checkpoint recovery after successful repair. This has been shown to be the most crucial function of Wip1 during a checkpoint response in G 2 . When cells depleted of Wip1 are treated with DNA-damaging agents, expression of cyclin-B (as well as a number of other cell-cycleregulatory proteins) decreases below the minimal level required for recovery (Lindqvist et al., 2009a) . The excessive reduction in cyclin-B expression is due to disproportionate activation of p53, which occurs in cells lacking Wip1 (Lindqvist et al., 2009a) . When expression of cyclin-B reduces below a critical threshold, cells lose the competence to recover. This demonstrates the importance of continued expression of the G 2 cluster of cell-cycle-regulated genes during a DNA-damage-induced arrest in G 2 . Indeed, it was demonstrated recently that minimal basal Cdk activity and transactivation by the transcriptional factor FoxM1 is needed to sustain cyclin-B expression at a level that can facilitate recovery once the checkpoint is silenced (Alvarez-Fernandez et al., 2010) .
Targeting checkpoint components in cancer therapy
Induction of cell death by excessive DNA damage represents the general principle of various cancer therapies, such as radiotherapy and a large proportion of chemotherapeutic therapies. This treatment targets genetically instable cancer cells (that are prone to cell death caused by genotoxic stress) but also hits normal tissues, especially those with high proliferative rates (such as epithelia in the gastrointestinal tract, hair follicles and bone marrow). Undesired targeting of healthy tissues by DNA-damaging agents represents a major problem in the clinics and limits efficiency in curing cancer.
A large subset of cancer types is incapable to establish the G 1 checkpoint, most often because of mutation or loss of the p53 tumor suppressor. Survival of these cells after a DNA-damaging treatment depends on activation of the G 2 checkpoint by the ATR/Chk1, p38/MK2 and ATM/Chk2 pathways (Wang et al., 1996; Zhao et al., 2002; Reinhardt et al., 2007; Jiang et al., 2009) . As a consequence, cells deficient of p53 are more vulnerable to inactivation of the G 2 checkpoint. This finding led to a novel strategy of chemosensitization, which combines treatment with a DNA-damaging agent with checkpoint inhibitor(s), thus preventing cell-cycle arrest and promoting cell death through mitotic catastrophe (Zhou and Bartek, 2004) (Figure 3 ). Previous studies showed that disruption of the Chk1 pathway, either by short interfering RNA or by treatment with the Chk1 inhibitor UCN-01, abrogates G 2 checkpoint activation induced by various DNA-damaging agents (including IR, 5-fluorouracil, cisplatin and campotecin), and leads to premature mitotic entry and cell death (Zhao et al., 2002; Xiao et al., 2003) . Subsequently, UCN-01 was used in phase-I trials in combination with cisplatin or irinotecan (Lara et al., 2005; Fracasso et al., 2010;  Figure 3 Checkpoint regulators and cancer therapy. Healthy cells with intact checkpoint components are able to fully activate the checkpoint after genotoxic stress. Tumor cells lacking functional p53 show a weak G 1 checkpoint but are still able to arrest in G 2 thanks to the ATR/Chk1 pathway. Exposure of these cells to DNA damage together with inhibition of Chk1 prevents checkpoint activation and leads to cell death by mitotic catastrophe. Tumor cells with wild-type p53 activate the checkpoint when exposed to DNA damage; however, stimulation of p53 by treatment with nutlin-3 or by inhibition of Wip1 phosphatase may lead to extensive p53 response and apoptotic cell death. Ma et al., 2011) . However, low specificity of UCN-01 for Chk1, as well as unfavorable pharmacokinetic profiles, prevented further use of UCN-01 in the clinic.
A new generation of ATP-competitive inhibitors of Chk1 shows higher selectivity toward Chk1/2 than UCN-01 (Ma et al., 2011) . For example, AZD7762 is comparably efficient toward Chk1 and Chk2 (IC 50 ¼ 5-10 nM), whereas the PF477736 and SCH900776 compounds selectively inhibit Chk1 (IC 50 ¼ 0.49 and 3 nM, respectively). Preclinical testing showed that these novel Chk1 inhibitors efficiently abrogate the G 2 checkpoint and sensitize p53-deficient cells to various DNA-damaging agents (Ma et al., 2011) , and it will be interesting to see how these inhibitors will perform in ongoing clinical trials. An important aspect that needs to be considered when using Chk1 inhibitors in the clinics is the role of the Chk1 outside the checkpoint control. Essential functions of Chk1 at the organismal level are welldocumented by the early embryonic lethality of Chk1-knockout mice as well as by severe defects in the mammary epithelia in the conditional Chk1 haploinsufficiency mouse model (Liu et al., 2000; Takai et al., 2000; Lam et al., 2004 ). Chk1 appears to be essential for maintenance of genome integrity by monitoring replication forks during normal S-phase progression (Takai et al., 2000; Syljuasen et al., 2005; Maya-Mendoza et al., 2007) . Thus inhibition of Chk1 together with treatments that cause stalling of replication forks may lead to irreversible replication fork collapse (Maya-Mendoza et al., 2007) . In addition, recent reports suggest that Chk1 may also contribute to the regulation of multiple aspects of unperturbed mitotic progression and cell division (Kramer et al., 2004; Zachos et al., 2007; Wilsker et al., 2008; Peddibhotla et al., 2009) . In this respect it might be beneficial to pharmacologically target downstream effectors of Chk1 specifically acting in the checkpoint pathway. A promising example is the Wee1 kinase, which acts downstream from Chk1 and regulates the G 2 /M transition. MK1775, a small-molecule inhibitor of Wee1, has recently been developed and showed chemosensitization of p53-deficient tumor cells and xenografts to gemcitabine, cisplatin and 5-fluorouracil, basically mimicking the effects of Chk1 inhibition (Hirai et al., 2009 (Hirai et al., , 2010 Rajeshkumar et al., 2011) . Similarly, the PD0166285 compound, which also inhibits Wee1, showed radiosensitization of various cancer cell lines (Wang et al., 2001 ). As discussed above, efficient checkpoint activation in cells that lack p53 requires also activity of Chk2, and it has been suggested that inhibition of the ATM/Chk2 pathway might sensitize p53-deficient tumors to DNA-damaging treatments or to poly-(ADP-ribose) polymerase inhibitors Anderson et al., 2011) . The use of Chk2 inhibitors might also bring additional benefits to surrounding healthy tissues expressing intact p53, as this could prevent an apoptotic response when Chk2 is inhibited (Zhou and Bartek, 2004) . By contrast, using Chk2 inhibitors on tumors, which retain wild-type p53, would dramatically increase their resistance to irradiation, leading to unfavorable clinical outcomes. Thus translation of this treatment strategy into the clinic will require the establishment of reliable predictive biomarkers (such as the status of the p53 and ATM pathways) and arguably will be limited to situations where tumor tissue samples are available . The observation that survival of p53-deficient cells exposed to genotoxic stress critically depends on the p38/MK2 pathway (Reinhardt et al., 2007) opens an intriguing possibility that patients receiving chemotherapy could potentially benefit from adjuvant therapy with p38 inhibitors; however this novel concept awaits experimental testing. Importantly, chemosensitization seems to work efficiently only in cells with a deficient p53 pathway (Zhou and Bartek, 2004; Ma et al., 2011) . Thus, although this strategy could be useful in cancers with mutated p53, there is a need to develop other strategies suitable for cancers that retain wild-type p53. Nutlin-3a was the first identified small-molecule antagonist of MDM2 that specifically blocks interaction between MDM2 and p53, leading to stabilization of p53 and inducing apoptosis or cellular senescence (Vassilev et al., 2004) . Strikingly, Nutlin-3a has a strong antitumor activity in tumor cells that retain wild-type p53, and promising preclinical results for Nutlin-3a were reported with various tumor types (Secchiero et al., 2011; Shen and Maki, 2011) . Similarly to Nutlin-3a, MI-219 blocks the MDM2-p53 interaction, but it shows higher affinity to MDM2 and excellent pharmacokinetic properties (Shangary et al., 2008) . Another potential pharmacological target in p53-positive tumors is Wip1, which acts in silencing of the G 2 checkpoint primarily through blocking the activity of p53 (Lindqvist et al., 2009a) . Depletion of Wip1 by antisense oligonucleotides or by RNA interference decreased viability in cell lines derived from neuroblastoma, glioma, breast adenocarcinoma and ovarian clear cell carcinoma, indicating that a subset of cancer patients suffering from p53-positive tumors could benefit from blocking the activity of Wip1 (Saito-Ohara et al., 2003; Rayter et al., 2008; Tan et al., 2009; Wang et al., 2011) . Indeed, PPM1D-knockout mice are viable and are protected from tumor development, indicating that loss of Wip1 activity is well-tolerated and may block tumor growth (Bulavin et al., 2004; Harrison et al., 2004) . However, development of specific Wip1 inhibitors represents a major challenge owing to the relatively shallow groove in the active site and the high homology with other PP2C family phosphatases (Harrison et al., 2004) . Cyclic phosphopeptides that mimic the binding of a substrate to the active site of Wip1 were shown to inhibit the activity of Wip1 in vitro; however their efficiency in inhibiting Wip1 in cells still requires further testing (Yamaguchi et al., 2006) . Chemical library screening yielded a compound that inhibited Wip1 activity in vitro and also increased the phosphorylation of p38, JNK and extracellular signalregulated kinase in transformed mouse embryonic fibroblasts (Belova et al., 2005) . However, as this compound affected the phosphorylation status of all mitogenactivated protein kinases, concerns remain about its specificity toward Wip1 and further modification may be necessary to generate a more selective inhibitor of Wip1 (Belova et al., 2005) . Another cell-permeable, smallmolecule inhibitor of Wip1 (CCT007093, IC 50 ¼ 8.4 mM) has recently been reported to decrease the viability of the MCF7, KPL1 and MCF3B tumor cell lines (Rayter et al., 2008) . Interestingly, this cytotoxic effect of Wip1 inhibition seems to be specific for tumors that overexpress Wip1, whereas cells with normal Wip1 levels tolerate the loss of Wip1 activity (Rayter et al., 2008) . The cell death induced by CCT007093 was dependent on p38, which is a well-described substrate of Wip1, and mimicked the effect of Wip1 RNA interference, indicating that the observed phenotype indeed results from specific inhibition of Wip1. It will be interesting to see how this promising Wip1 inhibitor will perform on a broader spectrum of tumors and in xenograft tumor models.
Concluding remarks
Over the last decades, we have gained a lot of insight into the mechanisms that act to coordinate the cellular response to DNA damage. It has become clear that various pathways can act in parallel to promote DNA repair and several others act together to inhibit cell-cycle progression. We have also learned that different components of the overall DDR can be lost in cancer cells, rendering them more dependent on the remaining intact pathways to promote repair and arrest the cell cycle. This has already led to the development of tailored therapies that exploit the cancer-specific DDR defect(s). These promising approaches call for a more advanced molecular understanding of the DDR as well as the development of small-molecule inhibitors targeting various components of the DNA-damage checkpoint, which can open additional avenues for personalized cancer treatment.
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